Fungal InfectionsNCT06483815
Fungal Infections During and After the SARS-CoV-2 Pandemic: A Retrospective Comparison
An observational study of Fungal Infections, run by Bekir Sami Uyanık at 1 site in Turkey (Türkiye).
Trial summary
his study aims to retrospectively compare fungal positivity rates between the SARS-CoV-2 pandemic and the post-pandemic periods. During the pandemic, Candida species had a positivity rate of 17.36%, and Aspergillus had a rate of 2.22%. Post-pandemic, these rates decreased to 9.29% and 1.00%, respectively. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Fungal Infections
- What is being tested?
- Culture, İsolation
- How many people
- 1,441 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jun 2024to 30 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients diagnosed with pneumonia according to clinical, laboratory and radiological data in the chest diseases, infectious diseases and intensive care unit of Hisar HIntercontinental Hospital
Who may be able to join
- Patients over 18 years of age of both genders
Who cannot join
- Patients under 18 years of age,
- Patients whose demographic, clinical and laboratory data investigated in the study could not be accessed, patients who were diagnosed with fungal infection during hospitalization
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Hisar Hospital Intercontinental
Istanbul, 34768
About this study
Official title: Comparative Retrospective Analysis of Fungal Positivity Rates During and Post-SARS-CoV-2 Pandemic Periods
his study aims to retrospectively compare fungal positivity rates between the SARS-CoV-2 pandemic and the post-pandemic periods. During the pandemic, Candida species had a positivity rate of 17.36%, and Aspergillus had a rate of 2.22%. Post-pandemic, these rates decreased to 9.29% and 1.00%, respectively. The overall fungal positivity rate decreased from 9.15% during the pandemic to 5.13% post-pandemic. Statistical analysis revealed a significant decrease in fungal positivity rates post-pandemic (p < 0.01). These findings underscore the effectiveness of post-pandemic healthcare interventions and infection control strategies.
Read the detailed description
The study aims to retrospectively compare fungal positivity rates by focusing on Candida and Aspergillus species during the SARS-CoV-2 pandemic and in the post-pandemic period. The dataset includes samples collected during the pandemic period (N=623) and the subsequent post-pandemic period (N=818). Fungal positivity rates were calculated and statistically analyzed using chi-square tests, and significance was determined as p<0.01.
During the SARS-CoV-2 pandemic, Candida species showed a positivity rate of 17.36%, while the rate in the post-pandemic period significantly decreased to 9.29% (p=0.002). In contrast, Aspergillus species did not show a significant change in positivity rates between the pandemic (2.22%) and post-pandemic (1.00%) periods (p=0.186, NS).
Overall, the study provides valuable insights into the epidemiology of fungal infections during and after the SARS-CoV-2 pandemic, suggesting possible shifts in fungal pathogen prevalence and healthcare priorities. The findings contribute to the development of targeted healthcare strategies and surveillance measures for fungal infections in the post-pandemic era.
Study Design: Retrospective comparative analysis
Data Analysis: Chi-square tests, p<0.01 considered significant
- Conditions
- Fungal Infections
- Being tested
- Culture, İsolation
- Keywords
- fungal infections, SARS-CoV-2, pandemic, post-pandemic
- Medical subject headings
- Mycoses
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Culture, İsolationDiagnostic test
Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.
| Study group | Role | What they receive |
|---|---|---|
| The percentages of fungus positivity in the SARS CoV-2 pandemic and SARS CoV-2 post-pandemic period | The study was conducted retrospectively, analyzing a total of 1441 patients. Among these, 623 were during the SARS-CoV-2 pandemic and 818 were in the post-pandemic period. Fungal positivity rates were calculated separately for different fungal agents including Candida species and Aspergillus. These rates were presented as percentages and statistically compared between the two periods. Receives: Diagnostic Test: Culture, İsolation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fungal positivity rates during the SARS-CoV-2 pandemic period and post-pandemic period
Fungal infection data from samples of patients, 623 of whom were during the SARS-CoV-2 epidemic and 818 of whom were in the post-epidemic period, were retrospectively examined. Fungal positivity rates for different fungal agents such as Candida species and Aspergillus were calculated separately and compared statistically.
Measured: 2020-2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2024
- Study start1 Jun 2024
- Primary completion20 Jul 2024
- Study completion30 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fungal InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 1,441 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bekir Sami Uyanık
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Bekir Sami Uyanık, Hisar Intercontinental Hospital
- Investigators
- Ramazan Gözüküçük, Study director, Hisar Hospital Responsible Manager
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06483815
- Sponsor's protocol ID
- ODFUNGAL
- Status last verified
- Sep 2026
- First submitted
- 29 Jun 2024
- Last updated
- 21 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Retrospective Analysis of Fungal Positivity Rates During and Post-SARS-CoV-2 Pandemic Periods
- ClinicalTrials.gov ID
- NCT06483815
- Acronym / sponsor ID
- ODFUNGAL
- Conditions
- Fungal Infections
- Keywords
- fungal infections, SARS-CoV-2, pandemic, post-pandemic
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,441 participants (actual)
- Lead sponsor
- Bekir Sami UyanıkUniversity, hospital or other
- Study start
- 1 Jun 2024 (actual)
- Primary completion
- 20 Jul 2024 (actual)
- Study completion
- 30 Oct 2025 (actual)
- First posted
- 3 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
his study aims to retrospectively compare fungal positivity rates between the SARS-CoV-2 pandemic and the post-pandemic periods. During the pandemic, Candida species had a positivity rate of 17.36%, and Aspergillus had a rate of 2.22%. Post-pandemic, these rates decreased to 9.29% and 1.00%, respectively. The overall fungal positivity rate decreased from 9.15% during the pandemic to 5.13% post-pandemic. Statistical analysis revealed a significant decrease in fungal positivity rates post-pandemic (p < 0.01). These findings underscore the effectiveness of post-pandemic healthcare interventions and infection control strategies.
Detailed description
The study aims to retrospectively compare fungal positivity rates by focusing on Candida and Aspergillus species during the SARS-CoV-2 pandemic and in the post-pandemic period. The dataset includes samples collected during the pandemic period (N=623) and the subsequent post-pandemic period (N=818). Fungal positivity rates were calculated and statistically analyzed using chi-square tests, and significance was determined as p<0.01.
During the SARS-CoV-2 pandemic, Candida species showed a positivity rate of 17.36%, while the rate in the post-pandemic period significantly decreased to 9.29% (p=0.002). In contrast, Aspergillus species did not show a significant change in positivity rates between the pandemic (2.22%) and post-pandemic (1.00%) periods (p=0.186, NS).
Overall, the study provides valuable insights into the epidemiology of fungal infections during and after the SARS-CoV-2 pandemic, suggesting possible shifts in fungal pathogen prevalence and healthcare priorities. The findings contribute to the development of targeted healthcare strategies and surveillance measures for fungal infections in the post-pandemic era.
Study Design: Retrospective comparative analysis
Data Analysis: Chi-square tests, p<0.01 considered significant
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| The percentages of fungus positivity in the SARS CoV-2 pandemic and SARS CoV-2 post-pandemic period | – | Diagnostic Test: Culture, İsolationThe study was conducted retrospectively, analyzing a total of 1441 patients. Among these, 623 were during the SARS-CoV-2 pandemic and 818 were in the post-pandemic period. Fungal positivity rates were calculated separately for different fungal agents including Candida species and Aspergillus. These rates were presented as percentages and statistically compared between the two periods. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with pneumonia according to clinical, laboratory and radiological data in the chest diseases, infectious diseases and intensive care unit of Hisar HIntercontinental Hospital
Key inclusion criteria (1 listed)
- Patients over 18 years of age of both genders
Key exclusion criteria (2 listed)
- Patients under 18 years of age,
- Patients whose demographic, clinical and laboratory data investigated in the study could not be accessed, patients who were diagnosed with fungal infection during hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Culture, İsolationData on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported. | Diagnostic test | The percentages of fungus positivity in the SARS CoV-2 pandemic and SARS CoV-2 post-pandemic period |
Primary outcome
Fungal positivity rates during the SARS-CoV-2 pandemic period and post-pandemic period
Time frame: 2020-2024
Fungal infection data from samples of patients, 623 of whom were during the SARS-CoV-2 epidemic and 818 of whom were in the post-epidemic period, were retrospectively examined. Fungal positivity rates for different fungal agents such as Candida species and Aspergillus were calculated separately and compared statistically.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Fungal Infections
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Active, not recruitingPhase 2
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
Pneumococcal Disease
Not yet recruiting
Early Pathophysiology of Hidradenitis Suppurativa and Prediction of the Risk of Progression: a Prospective Cohort
Hidradenitis Suppurativa (HS)
Active, not recruitingPhase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Mycosis Fungoides, Lymphomatoid Papulosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ramazan Gözüküçük study director
Hisar Hospital Responsible Manager
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Fungal Infections, run by Bekir Sami Uyanık at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fungal positivity rates during the SARS-CoV-2 pandemic period and post-pandemic period (time frame: 2020-2024). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.